Amphotericin B Cholesterol Complex Airway Surface Liquid pH
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cystic fibrosis patients suffer from chronic respiratory infections and malnutrition due to dysregulation of epithelial fluid transport caused by mutations in the CFTR gene, leading to thickened mucus and impaired airway surface liquid pH and antimicrobial activity, for which current treatments are inadequate.
Innovation Solution
A composition comprising amphotericin B and cholesterol, with a molar ratio ranging from 1:2.6 to 1:50, is used to increase the pH of airway surface liquid, thereby improving antimicrobial activity and airway protection by permeabilizing the apical membrane to bicarbonate, independent of CFTR function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amphotericin B is used to permeabilize the apical membrane to restore airway surface liquid pH and antimicrobial activity, then airway protection and bacterial killing are improved, but membrane disruption and potential toxicity may occur
Solution Approach 1:
Cholesterol acts as an intermediary substance that modulates the interaction between amphotericin B and the membrane. The cholesterol-amphotericin B complex allows controlled permeabilization of the apical membrane to restore bicarbonate transport and airway surface liquid pH, while the cholesterol component mitigates excessive membrane disruption and toxicity
Solution Approach 2:
The patent optimizes the molar ratio of amphotericin B to cholesterol (ranging from 1:2.6 to 1:50) to achieve the desired therapeutic effect. By adjusting this parameter, the complex provides sufficient membrane permeabilization to restore airway surface liquid pH and antimicrobial activity while minimizing harmful membrane disruption through the buffering effect of excess cholesterol
2Reliability
If a CFTR-dependent treatment is used to address epithelial fluid transport dysregulation, then specific CFTR mutation effects are targeted, but treatment effectiveness is limited by genotype variability and lack of efficacy for certain mutations
Solution Approach 1:
The patent extracts the downstream functional consequence of CFTR dysfunction (acidic airway surface liquid pH and impaired antimicrobial activity) as the primary treatment target, rather than addressing the upstream CFTR mutation itself. By directly correcting the airway surface liquid pH through amphotericin B-mediated membrane permeabilization and bicarbonate transport restoration, the treatment achieves genotype-agnostic efficacy across all CFTR mutation types
Solution Approach 2:
Instead of following the conventional approach of targeting CFTR function directly (which fails for many mutations), the patent inverts the therapeutic strategy by targeting the downstream effect (airway surface liquid pH and antimicrobial activity). This inverse approach bypasses the defective CFTR protein entirely and directly restores the functional outcome needed for airway protection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively increases airway surface liquid pH and antimicrobial activity, reducing viscosity and enhancing bacterial killing in cystic fibrosis patients, regardless of CFTR genotype, providing a genotype-agnostic treatment for cystic fibrosis.
Implementation Method 1
increasing the pH of airway surface liquid... by permeabilizing the apical membrane to bicarbonate
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
Provided herein are complexes comprising amphotericin B (AmB) or derivatives and sterols. Also provided herein are methods of treating cystic fibrosis using AmB or complexes comprising AmB or derivatives and sterols.